4 results
Approved WMOPending
The main objective of this Phase IIa/b study is to demonstrate the effectof zibotentan on HVPG, and that dapagliflozin can mitigate fluid retention safety concernsregarding its use in this population.
Approved WMOCompleted
ยท To evaluate the effect of zibotentan anddapagliflozin in combination and alone versusplacebo on UACR.
Approved WMOCompleted
Primary objective To investigate the safety and tolerability of CCS1477 as monotherapy and in combination.
Approved WMORecruiting
Primary- Continuation of treatment- SafetySecondairy- Documentation of tolerability